Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells

Journal of Neural Transmission

Volumn 120, Issue 3, 2013, Pages 435-444

  Inaba Hasegawa, Keiko ^a,b   Akao, Yukihiro ^c   Maruyama, Wakako ^d   Naoi, Makoto ^a,b  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c GIFU UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Gene induction; Parkinson's disease; R1 Sp1; Rasagiline; Selegiline ( )deprenyl ; Type A and B monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DACTINOMYCIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; RASAGILINE; SELEGILINE; TRANSCRIPTION FACTOR SP1;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE INDUCTION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

BLOTTING, WESTERN; CELL LINE; HUMANS; INDANS; ISOENZYMES; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEURONS; NEUROPROTECTIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SELEGILINE; TRANSFECTION;

EID: 84875725009     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0899-3     Document Type: Article

References (45)

1. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109-116 (Pubitemid 34056569)
2. Akao Y, Maruyama W, Shimizu S, Yi H, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and its inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82:913-923
3. Bar Am O, Amit T, Youdim MBH (2004) Contracting neuroprotective and neurotoxic action of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169-172 (Pubitemid 38368730)
4. Bar-Am O, Weinreb O, Amit T, Youdim MBH (2010) The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of anti-parkinsonian drug rasagiline. J Neurochem 112:1131-1137
5. Bortolato M, Chen K, Shih JC (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Delivery Rev 60:1527-1533
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72:248-254
7. Cao X, Li X-M, Mousseau DD (2009) Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signal pathways. Life Sci 85:262-268
8. Chen K, Ou X-M, Chen G, Choi SH, Shih JC (2005) R1, a novel repressor of the human monoamine oxidase A. J Biol Chem 280:11552-11559 (Pubitemid 40418467)
9. De Girolamo LA, Hargreaves AJ, Billett EE (2001) Protection from MPTP-induced neurotoxicity in differentiating N2a neuroblastoma cells. J Neurochem 76:650-660 (Pubitemid 32126064)
10. De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98:6168-6173 (Pubitemid 32488211)
11. Desagher S, Osen-Sand A, Nichols A et al (1999) Bid-induced conformational changes of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891-901 (Pubitemid 29238966)
12. Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, ReFaey HE, Carlson EC (2006) Therapeutic efficiency of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7:1513-1529 (Pubitemid 44718309)
13. Edmondson DE, Binda C, Mattevi A (2007) Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys 464:269-276 (Pubitemid 47210935)
14. Egashira T, Sakai K, Sakurai M, Takayama F (2003) Calcium disodium edetate enhances type A monoamine oxidase activity in monkey brain. Biol Trace Elem Res 94:203-211 (Pubitemid 37159518)
15. Finberg JPM, Youdim MBH (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43:1110-1118 (Pubitemid 36009364)
16. Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billet EE (2007) Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem 103:2189-2199 (Pubitemid 350173561)
17. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RN (1985) Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by monoamine oxidase B. J Neurochem 45:1049-1054 (Pubitemid 16258148)
18. Hirano F, Tanaka H, Hirano Y, Hiramoto M, Handa H, Makino I, Scheidereit C (1998) Functional interference of Sp1 and NF-κB through the same DNA binding site. Mol Cell Biol 18:1266-1274 (Pubitemid 28100890)
19. Hubalek F, Binda C, Ki M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47:1760-1768 (Pubitemid 38380919)
20. Hynson RMG, Kelly SM, Price NC, Ramsay RR (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophys Acta 1672:60-66 (Pubitemid 38410969)
21. Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M (2012) Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J Neural Transm 119:405-414
22. Konradi C, Riederer P, Youdim MB (1986) Hydrogen peroxide enhances the activity of monoamine oxidase type B but not of type-A: a pilot study. J Neural Transm Suppl 22:61-63
23. Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14:1684-1686
24. Lamensdorf I, Youdim MBH, Finberg JPM (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67:1532-1539 (Pubitemid 26314210)
25. Maruyama W, Naoi M (2012) Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to disease-modifying therapy? J Neural Transm. doi: 10.1007/s00702-0876-x
26. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44:293-400 (Pubitemid 37548404)
27. Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceut Des 16:2799-2817
28. Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M (2007) Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J Neural Transm Suppl 72:121-131
29. Naoi M, Maruyama W, Inaba-Hasegawa K, Akao Y (2011) Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Inter Rev Neurobiol 100:85-106
30. Ou X-M, Chen K, Shih JC (2006a) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923-10928 (Pubitemid 44148396)
31. Ou X-M, Chen K, Shih JC (2006b) Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 281:21512-21525 (Pubitemid 44115488)
32. Ou X-M, Lu D, Johnson C, Chen K, Youdim MBH, Rajkowska G, Shih JC (2009) Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res 16:148-159
33. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59:1937-1943 (Pubitemid 35424653)
34. Pizzinat N, Marchal-Victorion S, Maurel A, Ordener C, Bompart G, Parini A (2003) Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors. Am J Physiol Renal Physiol 284:F167-F174
35. Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033-2043 (Pubitemid 38967728)
36. Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: from genes to behavior. Ann Rev Neurosci 22:197-217 (Pubitemid 29144886)
37. Shih JC, Boyang J, Chen K (2011) Transcriptional regulation and multiple functions of MAO genes. J Neural Transm 118:979-986
38. Tazik S, Johnson S, Lu D, Johnson C, Youdim MBH, Stockmeier OuX-M (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurosci Res 15:284-290
39. Wang J, Edmondson DE (2011) Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Biochemistry 50:2499-2505
40. Wong WK, Ou XM, Chen K, Shih JC (2002) Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. J Biol Chem 277:22222-22230 (Pubitemid 34967188)
41. Wu JB, Shih JC (2011) Valproic acid induces monoamine oxidase A via Akt/Forkhead Box O1 activation. Mol Pharmacol 80:714-723
42. Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M (2006) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541-549
43. Youdim MBH, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147:S287-S296 (Pubitemid 43077287)
44. Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309
45. Zhu W, Xie W, Pan T, Jankovic J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capacities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105:1970-1978 (Pubitemid 351678517)